|
Name: Methyprylon
Type: Sedative
AKA: Noludar
|
|
II. Natural Derivative
Synthetic substance, no natural derivative
 |
|
III. Chemical Profile (IUPAC name)
|
|
IV. History
Methyprylon, a sedative and hypnotic, was introduced in the 1950s. It was used to treat insomnia but has largely been replaced by newer medications with fewer side effects.
|
|
V. Legal Information
Methyprylon, a sedative, is classified as a Schedule IV controlled substance in the US, allowing limited medical use. It is similarly regulated in many countries due to its potential for abuse and dependency. The UNODC and other regulatory bodies emphasize the need for balanced regulation to ensure safe medical use while preventing misuse.
US Federal Schedule - III
Schedule III drugs, substances, or chemicals are defined as drugs with a moderate to low potential for physical and psychological dependence. Schedule III drugs abuse potential is less than Schedule I and Schedule II drugs but more than Schedule IV. Some examples of Schedule III drugs are: products containing less than 90 milligrams of codeine per dosage unit (Tylenol with codeine), ketamine, anabolic steroids, testosterone.
Key US Federal Policies:
Controlled Substances Act. Public Law: Public Law 91-513 (text can be found on GovInfo) (https://www.dea.gov/drug-information/csa). Date enacted: October 27, 1970.
|
|
VI. Physical Effects
Methyprylon, a sedative-hypnotic drug introduced in the 1950s, acts as a downer, inducing sleep and sedation. Physical impacts include decreased heart rate, respiratory depression, and dilated pupils. Short-term use is effective for sleep disorders, but long-term use can lead to tolerance and dependence. Overdose risks include severe respiratory depression and potential death. Safe use requires careful dosing. Recent research focuses on its efficacy in treating insomnia and its safety profile compared to other sedatives.  |
|
VII. Psychological Effects
Methyprylon, a sedative, causes mood enhancement and sedation. Immediate effects include reduced anxiety and cognitive impairment. Long-term use may result in dependence, tolerance, and cognitive deficits. Chronic use is associated with mood disorders and potential addiction. Recent studies highlight its effectiveness as a sedative but also emphasize risks of long-term use and dependence.
 |
|
VIII. Culture
Methyprylon is a sedative-hypnotic used to treat insomnia, classifying it as a downer. Short-term use promotes sleep, while long-term use can lead to dependence and cognitive impairment. Overdose risks include severe sedation and respiratory depression. Safe dosages are typically under 300 mg per day. Recent research highlights its efficacy in sleep disorders but warns of addiction risks. Physical effects include drowsiness, impaired coordination, and potential respiratory depression.
 |